Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment.

Vidisheva AP, Wang J, Spektor TM, Bitran JD, Lutzky J, Tabbara IA, Ye JZ, Ailawadhi S, Stampleman LV, Steis RG, Moezi MM, Swift RA, Maluso TM, Udd KA, Eshaghian S, Nassir Y, Berenson JR.

Support Care Cancer. 2017 Oct;25(10):3217-3224. doi: 10.1007/s00520-017-3732-6. Epub 2017 Apr 28.

PMID:
28455546
2.

Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study.

Belani CP, Schreeder MT, Steis RG, Guidice RA, Marsland TA, Butler EH, Ramalingam SS.

Cancer. 2008 Nov 1;113(9):2512-7. doi: 10.1002/cncr.23902.

3.

Bone marrow transplantation: cancer therapy comes of age.

Owen P, Connaghan DG, Holland HK, Steis RG.

J Med Assoc Ga. 1998 Apr;87(2):145-6, 148. No abstract available.

PMID:
16259263
4.

Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.

Meluch AA, Greco FA, Morrissey LH, Raefsky EL, Steis RG, Butts JA, Hainsworth JD; Minnie Pearl Cancer Research Network.

Cancer. 2003 Nov 15;98(10):2192-8.

5.

Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network.

Meluch AA, Greco FA, Burris HA 3rd, O'Rourke T, Ortega G, Steis RG, Morrissey LH, Johnson V, Hainsworth JD.

J Clin Oncol. 2001 Jun 15;19(12):3018-24.

PMID:
11408496
6.

A phase II study of carboplatin, cisplatin, interferon-alpha, and tamoxifen for patients with metastatic melanoma.

Gause BL, Sharfman WH, Janik JE, Curti BD, Steis RG, Urba WJ, Smith JW 2nd, Alvord WG, Longo DL.

Cancer Invest. 1998;16(6):374-80.

PMID:
9679527
7.

A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma.

Fenton RG, Steis RG, Madara K, Zea AH, Ochoa AC, Janik JE, Smith JW 2nd, Gause BL, Sharfman WH, Urba WJ, Hanna MG, DeJager RL, Coyne MX, Crouch RD, Gray P, Beveridge J, Creekmore SP, Holmlund J, Curti BD, Sznol M, Longo DL.

J Immunother Emphasis Tumor Immunol. 1996 Sep;19(5):364-74.

PMID:
8941876
8.

Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.

Gause BL, Sznol M, Kopp WC, Janik JE, Smith JW 2nd, Steis RG, Urba WJ, Sharfman W, Fenton RG, Creekmore SP, Holmlund J, Conlon KC, VanderMolen LA, Longo DL.

J Clin Oncol. 1996 Aug;14(8):2234-41.

PMID:
8708712
9.

Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma.

Janik JE, Miller LL, Longo DL, Powers GC, Urba WJ, Kopp WC, Gause BL, Curti BD, Fenton RG, Oppenheim JJ, Conlon KC, Holmlund JT, Sznol M, Sharfman WH, Steis RG, Creekmore SP, Alvord WG, Beauchamp AE, Smith JW 2nd.

J Natl Cancer Inst. 1996 Jan 3;88(1):44-9.

PMID:
8847725
10.

Clinical relevance of recombinant interferon-alpha 2a antibodies in patients with hairy cell leukemia.

Steis RG, Longo DL.

J Interferon Res. 1994 Aug;14(4):207-9. No abstract available.

PMID:
7822877
11.
12.

Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma.

Horowitz ME, Kinsella TJ, Wexler LH, Belasco J, Triche T, Tsokos M, Steinberg SM, McClure L, Longo DL, Steis RG, et al.

J Clin Oncol. 1993 Oct;11(10):1911-8.

PMID:
8410118
13.

Immunomodulatory effects of interferon-gamma in patients with metastatic malignant melanoma.

Kopp WC, Smith JW 2nd, Ewel CH, Alvord WG, Main C, Guyre PM, Steis RG, Longo DL, Urba WJ.

J Immunother Emphasis Tumor Immunol. 1993 Apr;13(3):181-90.

PMID:
8471592
14.

Dose-related immunologic effects of levamisole in patients with cancer.

Janik J, Kopp WC, Smith JW 2nd, Longo DL, Alvord WG, Sharfman WH, Fenton RG, Sznol M, Steis RG, Creekmore SP, et al.

J Clin Oncol. 1993 Jan;11(1):125-35.

PMID:
8418223
15.

The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies.

Smith JW 2nd, Urba WJ, Curti BD, Elwood LJ, Steis RG, Janik JE, Sharfman WH, Miller LL, Fenton RG, Conlon KC, et al.

J Clin Oncol. 1992 Jul;10(7):1141-52.

PMID:
1607919
16.

Intensive therapy with cisplatin, interleukin-2 and interferon-alpha-2a in patients with metastatic melanoma. A phase II Study.

Sznol M, Steis RG, Smith JW 2nd, Janik JE, Sharfman WH, Urba WJ, Fenton RG, Creekmore SP, Beveridge J, Longo DL.

Online J Curr Clin Trials. 1992 Jul 1;Doc No 9:[3841 words; 32 paragraphs].

PMID:
1343617
17.

Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.

Sznol M, Clark JW, Smith JW 2nd, Steis RG, Urba WJ, Rubinstein LV, VanderMolen LA, Janik J, Sharfman WH, Fenton RG, et al.

J Natl Cancer Inst. 1992 Jun 17;84(12):929-37.

PMID:
1629914
18.

Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects.

Ewel CH, Urba WJ, Kopp WC, Smith JW 2nd, Steis RG, Rossio JL, Longo DL, Jones MJ, Alvord WG, Pinsky CM, et al.

Cancer Res. 1992 Jun 1;52(11):3005-10.

19.

Anti-CD3 monoclonal antibody treatment of patients with CD3-negative tumors: a phase IA/B study.

Urba WJ, Ewel C, Kopp W, Smith JW 2nd, Steis RG, Ashwell JD, Creekmore SP, Rossio J, Sznol M, Sharfman W, et al.

Cancer Res. 1992 May 1;52(9):2394-401.

20.

Kinetics of recovery of CD4+ T cells in peripheral blood of deoxycoformycin-treated patients.

Steis RG, Urba WJ, Kopp WC, Alvord WG, Smith JW 2nd, Longo DL.

J Natl Cancer Inst. 1991 Nov 20;83(22):1678-9. No abstract available.

PMID:
1684207
21.

The in vivo immunomodulatory effects of recombinant interferon gamma plus recombinant tumor necrosis factor-alfa.

Urba WJ, Kopp WC, Clark JW, Smith JW 2nd, Steis RG, Huber C, Coggin D, Longo DL.

J Clin Oncol. 1991 Oct;9(10):1831-9.

PMID:
1919633
22.

Phase I evaluation of recombinant tumor necrosis factor given in combination with recombinant interferon-gamma.

Smith JW 2nd, Urba WJ, Clark JW, Longo DL, Farrell M, Creekmore SP, Conlon KC, Jaffe H, Steis RG.

J Immunother (1991). 1991 Oct;10(5):355-62.

PMID:
1790143
23.

Loss of interferon antibodies during prolonged continuous interferon-alpha 2a therapy in hairy cell leukemia.

Steis RG, Smith JW 2nd, Urba WJ, Venzon DJ, Longo DL, Barney R, Evans LM, Itri LM, Ewel CH.

Blood. 1991 Feb 15;77(4):792-8.

24.

Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.

Clark JW, Smith JW 2nd, Steis RG, Urba WJ, Crum E, Miller R, McKnight J, Beman J, Stevenson HC, Creekmore S, et al.

Cancer Res. 1990 Nov 15;50(22):7343-50.

25.

Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity.

Steis RG, Urba WJ, VanderMolen LA, Bookman MA, Smith JW 2nd, Clark JW, Miller RL, Crum ED, Beckner SK, McKnight JE, et al.

J Clin Oncol. 1990 Oct;8(10):1618-29.

PMID:
2213099
26.

Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancer.

Kragel AH, Travis WD, Steis RG, Rosenberg SA, Roberts WC.

Cancer. 1990 Oct 1;66(7):1513-6.

PMID:
2208002
27.

Syngeneic bone marrow transplantation and adoptive transfer of peripheral blood lymphocytes combined with zidovudine in human immunodeficiency virus (HIV) infection.

Lane HC, Zunich KM, Wilson W, Cefali F, Easter M, Kovacs JA, Masur H, Leitman SF, Klein HG, Steis RG, et al.

Ann Intern Med. 1990 Oct 1;113(7):512-9.

PMID:
1975487
28.

Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy.

Conlon KC, Urba WJ, Smith JW 2nd, Steis RG, Longo DL, Clark JW.

Cancer. 1990 May 15;65(10):2237-42.

PMID:
2346907
29.

Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine.

Urba WJ, Hartmann LC, Longo DL, Steis RG, Smith JW 2nd, Kedar I, Creekmore S, Sznol M, Conlon K, Kopp WC, et al.

Cancer Res. 1990 May 15;50(10):2979-86.

30.

Erythrocytosis in hairy cell leukaemia following therapy with interferon alpha.

Steis RG, VanderMolen LA, Lawrence J, Sing G, Ruscetti F, Smith JW 2nd, Urba WJ, Clark J, Longo DL.

Br J Haematol. 1990 May;75(1):133-5. No abstract available.

PMID:
2375913
31.

Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase Ib trial.

Steis RG, VanderMolen LA, Longo DL, Clark JW, Smith JW 2nd, Kopp WC, Ruscetti FW, Creekmore SP, Elwood LJ, Hursey J, et al.

J Natl Cancer Inst. 1990 Apr 18;82(8):697-703.

PMID:
2138680
32.

Treatment of hairy cell leukemia with alternating cycles of pentostatin and recombinant leukocyte A interferon: results of a phase II study.

Martin A, Nerenstone S, Urba WJ, Longo DL, Lawrence JB, Clark JW, Hawkins MJ, Creekmore SP, Smith JW 2nd, Steis RG.

J Clin Oncol. 1990 Apr;8(4):721-30.

PMID:
2313337
33.

Toxicity, immunogenicity, and tumor radioimmunodetecting ability of two human monoclonal antibodies in patients with metastatic colorectal carcinoma.

Steis RG, Carrasquillo JA, McCabe R, Bookman MA, Reynolds JC, Larson SM, Smith JW 2nd, Clark JW, Dailey V, Del Vecchio S, et al.

J Clin Oncol. 1990 Mar;8(3):476-90.

PMID:
1689772
34.

Low- versus high-dose interferon alfa-2a in relapsed indolent non-Hodgkin's lymphoma.

VanderMolen LA, Steis RG, Duffey PL, Foon KA, Smith JW 2nd, Clark JW, Conlon K, Stevenson HC, Urba WJ, Hartmann LC, et al.

J Natl Cancer Inst. 1990 Feb 7;82(3):235-8. No abstract available.

PMID:
2296053
36.

Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome.

Kohn EC, Steis RG, Sausville EA, Veach SR, Stocker JL, Phelps R, Franco S, Longo DL, Bunn PA, Ihde DC.

J Clin Oncol. 1990 Jan;8(1):155-60.

PMID:
2295906
37.

Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer.

Urba WJ, Steis RG, Longo DL, Kopp WC, Maluish AE, Marcon L, Nelson DL, Stevenson HC, Clark JW.

Cancer Res. 1990 Jan 1;50(1):185-92.

PMID:
2293554
38.

Diffuse osteosclerosis in hairy cell leukemia.

VanderMolen LA, Urba WJ, Longo DL, Lawrence J, Gralnick H, Steis RG.

Blood. 1989 Nov 1;74(6):2066-9.

39.

Use of prophylactic antibiotics for prevention of intravascular catheter-related infections in interleukin-2-treated patients.

Hartmann LC, Urba WJ, Steis RG, Smith JW 2nd, Vander Molen LA, Creekmore SP, Sznol M, Casciano MA, Engler N, Longo DL.

J Natl Cancer Inst. 1989 Aug 2;81(15):1190-3. No abstract available.

PMID:
2787409
40.

Adrenal insufficiency and interleukin-2 therapy.

VanderMolen LA, Smith JW 2nd, Longo DL, Steis RG, Kremers P, Sznol M.

Ann Intern Med. 1989 Jul 15;111(2):185. No abstract available.

PMID:
2787137
41.

Hypothyroidism after interleukin-2 therapy.

Hartmann LC, Urba WJ, Steis RG, Smith JW 2nd, VanderMolen L, Creekmore SP, Longo DL.

J Clin Oncol. 1989 May;7(5):686-7. No abstract available.

PMID:
2785167
42.

Intraperitoneal lymphokine-activated killer cell/interleukin-2 therapy in patients with intra-abdominal cancer: immunologic considerations.

Urba WJ, Clark JW, Steis RG, Bookman MA, Smith JW 2nd, Beckner S, Maluish AE, Rossio JL, Rager H, Ortaldo JR, et al.

J Natl Cancer Inst. 1989 Apr 19;81(8):602-11.

PMID:
2495368
43.

Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma.

Miller RL, Steis RG, Clark JW, Smith JW 2nd, Crum E, McKnight JE, Hawkins MJ, Jones MJ, Longo DL, Urba WJ.

Cancer Res. 1989 Apr 1;49(7):1871-6.

44.

Deoxycoformycin-induced immunosuppression in patients with hairy cell leukemia.

Urba WJ, Baseler MW, Kopp WC, Steis RG, Clark JW, Smith JW 2nd, Coggin DL, Longo DL.

Blood. 1989 Jan;73(1):38-46.

45.

Rearrangement of both immunoglobulin and T-cell receptor genes in a prolymphocytic variant of hairy cell leukemia patient resistant to interferon-alpha.

Giardina SL, Young HA, Faltynek CR, Jaffe ES, Clark JW, Steis RG, Urba WJ, Mathieson BJ, Gralnick H, Lawrence J, et al.

Blood. 1988 Nov;72(5):1708-16. Erratum in: Blood 1989 Feb;73(2):624.

46.

Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies.

Steis RG, Smith JW 2nd, Urba WJ, Clark JW, Itri LM, Evans LM, Schoenberger C, Longo DL.

N Engl J Med. 1988 Jun 2;318(22):1409-13.

PMID:
3367950
47.

Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia.

Steis RG, Marcon L, Clark J, Urba W, Longo DL, Nelson DL, Maluish AE.

Blood. 1988 May;71(5):1304-9.

49.

The determination of an immunologically active dose of interferon-gamma in patients with melanoma.

Maluish AE, Urba WJ, Longo DL, Overton WR, Coggin D, Crisp ER, Williams R, Sherwin SA, Gordon K, Steis RG.

J Clin Oncol. 1988 Mar;6(3):434-45.

PMID:
3127550
50.

Indium-111 T101 monoclonal antibody is superior to iodine-131 T101 in imaging of cutaneous T-cell lymphoma.

Carrasquillo JA, Mulshine JL, Bunn PA Jr, Reynolds JC, Foon KA, Schroff RW, Perentesis P, Steis RG, Keenan AM, Horowitz M, et al.

J Nucl Med. 1987 Mar;28(3):281-7.

Supplemental Content

Loading ...
Support Center